N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Phase 3 ClinicalTrials.gov

Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease

Sponsor: Regeneron Pharmaceuticals • ClinicalTrials.gov ID: NCT07318610

Registry updated: 2026-10-15
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

This study is researching 2 different experimental drugs called REGN7508 and REGN9933. The study is focused on people who have Peripheral Artery Disease (PAD), which means that the blood vessels in their arms and legs have become too narrow. People with PAD have a higher risk of getting blood clots after procedures like Lower Extremity Revascularization (LER), a procedure to improve blood flow in the legs and feet. The aim of this study is to see how well REGN7508 and REGN9933 prevent life-threatening blood clots in participants with PAD who have recently had LER. The effects of REGN7508 and REGN9933, individually, will also be compared to rivaroxaban and a placebo. The study is looking at several other research questions, including: * What side effects might happen from taking the study drugs and how do they compare to the side effects of rivaroxaban * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drugs (which could make the drugs less effective or could lead to side effects) * If the study drugs affect the ability of the blood to clot normally

Interventions

  • REGN7508 (Drug)
    Administered per the protocol
  • REGN9933 (Drug)
    Administered per the protocol
  • Placebo (Drug)
    Administered per the protocol
  • Rivaroxaban (Drug)
    Administered per the protocol

Eligibility criteria

Key Inclusion Criteria: 1. Successful LER distal to the external iliac artery for ischemia due to atherosclerotic disease within 10 days prior to randomization as described in the protocol 2. At least 1 of the following enrichment factors for major thrombotic vascular events: 1. Bypass with prosthetic graft 2. Endovascular treatment with stenting 3. Target lesion length \>15 cm 4. History of LER or amputation for PAD prior to qualifying LER 5. Type 2 diabetes mellitus requiring pharmacologic treatment 6. Comorbid symptomatic coronary artery disease as described in the protocol 7. Chronic kidney disease as described in the protocol 8. Age ≥75 years Key Exclusion Criteria: 1. Has any active clinical condition requiring chronic therapeutic anticoagulation after the index revascularization including known triple positive antiphospholipid syndrome 2. Has known bleeding diathesis, platelet count \<50,000/mm\^3 or history of non-traumatic intracerebral hemorrhage, known cerebral amyloid angiopathy, or known unrepaired cerebrovascular malformations 3. Has recent coronary revascularization as described in the protocol 4. For Cohort 2 only: Has estimated Glomerular Filtration Rate (eGFR) \<15 mL/min/1.73m\^2 within 14 days prior to randomization or on dialysis or expected to be started on dialysis within the next 12 weeks starting from randomization 5. Has any other condition or therapy which would make the participant unsuitable for this study or not allow participation for the full planned study period 6. Has allergy, hypersensitivity, or other contraindication to REGN7508, REGN9933, or rivaroxaban (Cohort 2 only) or their excipients Note: Other Protocol Defined Inclusion/ Exclusion Criteria Apply

Conditions

Peripheral Artery Disease (PAD)

Locations

  • Lake Martin Medical and Vascular Center — Alexander City, Alabama, United States
  • Axsendo Clinical Research, Integrated Medical Services — Avondale, Arizona, United States
  • Applied Research Center of Arkansas — Little Rock, Arkansas, United States
  • Angel City Research, Inc. — Los Angeles, California, United States
  • Pacific Cardiovascular and Vein Institute — Oxnard, California, United States
  • Interventional Cardiology Medical Group — West Hills, California, United States
  • Nature Coast Clinical Research - Cardiology — Crystal River, Florida, United States
  • Cardiovascular Institute of Northwest Florida, Main Office — Panama City, Florida, United States
  • Tampa Cardiovascular Interventions and Research — Tampa, Florida, United States
  • Lutheran Medical Group LLC dba Lutheran Health Physicians — Fort Wayne, Indiana, United States
  • Profound Research, Powers Health Medical Group — Munster, Indiana, United States
  • Cardiovascular Solutions — Shreveport, Louisiana, United States
  • Accellacare of Piedmont, Piedmont Healthcare — Mooresville, North Carolina, United States
  • Hightower Clinical — Oklahoma City, Oklahoma, United States
  • Apex Research Foundation, LLC — Jackson, Tennessee, United States
  • Tennova TCMC — Knoxville, Tennessee, United States
  • Vanderbilt Heart and Vascular Tullahoma, Cardiology and Vascular Associates — Tullahoma, Tennessee, United States
  • PharmaTex Research — Amarillo, Texas, United States
  • Vital Heart and Vein — Cypress, Texas, United States
  • Epic Medical Research — DeSoto, Texas, United States
  • Epic Medical Research-Plano — Plano, Texas, United States
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record